Skip to main
IFRX

InflaRx (IFRX) Stock Forecast & Price Target

InflaRx (IFRX) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

InflaRx is a promising clinical-stage biopharmaceutical company that specializes in developing potent inhibitors of the complement activation factor, C5a, and its receptor, C5aR, for the treatment of various autoimmune and inflammatory diseases. The company recently announced positive financial results for the first quarter of 2026, with a significant increase in cash and marketable securities, which is expected to provide runway through 2029. In addition, InflaRx's product candidate, vilobelimab, has demonstrated promising disease-modifying clinical activity and tolerability in multiple clinical settings, making it a potential game-changer in the biotechnology industry.

Bears say

InflaRx is facing potential risks and challenges financially as they lack commercial assets and depend heavily on securing partnerships and funding in order to progress their pipeline. While their product candidate, izicopan, shows potential for autoimmune and inflammatory diseases, its efficacy and position in the market remains uncertain. Additionally, IFRX faces competition in the increasingly competitive CSU and HS market, and the success of their therapies heavily relies on positive clinical trial results and regulatory approvals.

InflaRx (IFRX) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About InflaRx (IFRX) Forecast

Analysts have given InflaRx (IFRX) a Buy based on their latest research and market trends.

According to 5 analysts, InflaRx (IFRX) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

InflaRx (IFRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.